Hydroxychloroquine + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Sjögren's Syndrome
Conditions
Primary Sjögren's Syndrome
Trial Timeline
Mar 1, 2008 → May 1, 2012
NCT ID
NCT00632866About Hydroxychloroquine + Placebo
Hydroxychloroquine + Placebo is a phase 3 stage product being developed by Sanofi for Primary Sjögren's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00632866. Target conditions include Primary Sjögren's Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Primary Sjögren's Syndrome were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00632866 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Sjögren's Syndrome